Archive · 10 Jun 2025
Akums Drugs Rebounds: Should Investors Buy?
Akums Drugs, a mid-cap pharma company, has seen its stock price increase by 35% since April.
This rise comes after a period of market uncertainty.
Analysts at ICICI Securities are optimistic, highlighting strong CDMO business growth and potential for future expansion.
The company has significant cash reserves and plans to grow its export business.
Technical analysis also suggests positive momentum, with a potential breakout expected.
Investors are watching the stock to see if it can sustain this growth.
Akums Drugs stock has risen approximately 35% since April lows.
The stock reached ₹568 after a low of around ₹421.
CDMO business grew by 14.8% in Q4 FY25.
ICICI Securities maintains a BUY rating for the stock.
Technical analysis suggests the stock is positioned for an upside.
- Who
- Akums Drugs and Pharmaceuticals Ltd
- What
- Akums Drugs stock rebounded 35% from April lows.
- When
- Since April 2025, Q4 FY25
- Where
- BSE
- Why
- Rebound attributed to CDMO business growth and positive analyst ratings.
Neutral View
Optimistic View
Analyst Rating and Outlook
Neutral View
N/A
Optimistic View
ICICI Securities maintains a BUY rating with a target price of ₹710, expecting growth in CDMO and export operations.
- Company
- Akums Drugs and Pharmaceuticals Ltd
- Stock Price Low (April 7, 2025)
- ₹421
- Current Stock Price
- ₹568
- Recent Gain
- 35%
- Cash on Hand
- ₹1500 crore
- CDMO Business Growth (Q4 FY25)
- 14.8%
- Expected Export Growth (FY26)
- 20%
